BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 28238711)

  • 1. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.
    Amarenco P; Albers GW; Denison H; Easton JD; Evans SR; Held P; Hill MD; Jonasson J; Kasner SE; Ladenvall P; Minematsu K; Molina CA; Wang Y; Wong KSL; Johnston SC;
    Lancet Neurol; 2017 Apr; 16(4):301-310. PubMed ID: 28238711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin.
    Amarenco P; Denison H; Evans SR; Himmelmann A; James S; Knutsson M; Ladenvall P; Molina CA; Wang Y; Johnston SC;
    Stroke; 2020 Dec; 51(12):3504-3513. PubMed ID: 33198608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
    Johnston SC; Amarenco P; Albers GW; Denison H; Easton JD; Evans SR; Held P; Jonasson J; Minematsu K; Molina CA; Wang Y; Wong KS;
    N Engl J Med; 2016 Jul; 375(1):35-43. PubMed ID: 27160892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design.
    Johnston SC; Amarenco P; Albers GW; Denison H; Easton JD; Held P; Jonasson J; Minematsu K; Molina CA; Wong LK
    Int J Stroke; 2015 Dec; 10(8):1304-8. PubMed ID: 26311628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
    Amarenco P; Albers GW; Denison H; Easton JD; Evans SR; Held P; Hill MD; Jonasson J; Kasner SE; Ladenvall P; Minematsu K; Molina CA; Wang Y; Wong KSL; Johnston SC;
    Stroke; 2017 Sep; 48(9):2480-2487. PubMed ID: 28720658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).
    Wang Y; Minematsu K; Wong KS; Amarenco P; Albers GW; Denison H; Easton JD; Evans SR; Held P; Jonasson J; Molina CA; Johnston SC;
    Stroke; 2017 Jan; 48(1):167-173. PubMed ID: 27899747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).
    Easton JD; Aunes M; Albers GW; Amarenco P; Bokelund-Singh S; Denison H; Evans SR; Held P; Jahreskog M; Jonasson J; Minematsu K; Molina CA; Wang Y; Wong KSL; Johnston SC;
    Circulation; 2017 Sep; 136(10):907-916. PubMed ID: 28655834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial.
    Wong KSL; Amarenco P; Albers GW; Denison H; Easton JD; Evans SR; Held P; Himmelmann A; Kasner SE; Knutsson M; Ladenvall P; Minematsu K; Molina CA; Wang Y; Johnston SC;
    Stroke; 2018 Jul; 49(7):1678-1685. PubMed ID: 29915123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Acute S
    Johnston SC; Amarenco P; Denison H; Evans SR; Himmelmann A; James S; Knutsson M; Ladenvall P; Molina CA; Wang Y;
    Int J Stroke; 2019 Oct; 14(7):745-751. PubMed ID: 30747613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial.
    Wang Y; Chen W; Lin Y; Meng X; Chen G; Wang Z; Wu J; Wang D; Li J; Cao Y; Xu Y; Zhang G; Li X; Pan Y; Li H; Zhao X; Liu L; Lin J; Dong K; Jing J; Johnston SC; Wang D; Wang Y;
    BMJ; 2019 Jun; 365():l2211. PubMed ID: 31171523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.
    Molina CA; Johnston SC; Ladenvall P; Amarenco P; Albers GW; Denison H; Easton JD; Evans SR; Held P; Knutsson M; Minematsu K; Röther J; Wang Y; Wong KSL;
    Stroke; 2019 Mar; 50(3):675-682. PubMed ID: 30776996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial.
    Wong KS; Chen C; Fu J; Chang HM; Suwanwela NC; Huang YN; Han Z; Tan KS; Ratanakorn D; Chollate P; Zhao Y; Koh A; Hao Q; Markus HS;
    Lancet Neurol; 2010 May; 9(5):489-97. PubMed ID: 20335070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.
    Easton JD; Denison H; Evans SR; Knutsson M; Amarenco P; Albers GW; Ladenvall P; Minematsu K; Molina CA; Wang Y; Wong KL; Johnston SC;
    Int J Stroke; 2019 Dec; 14(9):908-914. PubMed ID: 31092152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.
    Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox KM; Hennerici MG; Mattle HP; Rothwell PM; de Cordoüe A; Fratacci MD;
    Lancet; 2011 Jun; 377(9782):2013-22. PubMed ID: 21616527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
    Sharma M; Molina CA; Toyoda K; Bereczki D; Bangdiwala SI; Kasner SE; Lutsep HL; Tsivgoulis G; Ntaios G; Czlonkowska A; Shuaib A; Amarenco P; Endres M; Yoon BW; Tanne D; Toni D; Yperzeele L; von Weitzel-Mudersbach P; Sampaio Silva G; Avezum A; Dawson J; Strbian D; Tatlisumak T; Eckstein J; Ameriso SF; Weber JR; Sandset EC; Goar Pogosova N; Lavados PM; Arauz A; Gailani D; Diener HC; Bernstein RA; Cordonnier C; Kahl A; Abelian G; Donovan M; Pachai C; Li D; Hankey GJ
    Lancet Neurol; 2024 Jan; 23(1):46-59. PubMed ID: 38101902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
    Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
    Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New opportunities to optimize antithrombotic therapy for secondary stroke prevention.
    Kim AS; Easton JD
    Int J Stroke; 2019 Apr; 14(3):220-222. PubMed ID: 30722755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial.
    Dengler R; Diener HC; Schwartz A; Grond M; Schumacher H; Machnig T; Eschenfelder CC; Leonard J; Weissenborn K; Kastrup A; Haberl R;
    Lancet Neurol; 2010 Feb; 9(2):159-66. PubMed ID: 20060783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.
    ; Halkes PH; van Gijn J; Kappelle LJ; Koudstaal PJ; Algra A
    Lancet Neurol; 2007 Feb; 6(2):115-24. PubMed ID: 17239798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.